Asselah T, Pol S, Hezode C. et al. Efficacy and Safety of Elbasvir/Grazoprevir for 8 or 12 Weeks in Participants with Hepatitis C Virus Genotype 4 Infection. Hepatology 2018; 68: 385a-385a
Download Bibliographical Data
We do not assume any responsibility for the contents of the web pages of other providers.